The mean values of correctly memorized foreground characters and users’ SDNN in different background line orientations. by Yanqun Huang (7487657)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Result of the effect sizes for <i>β</i> = 1/5. by Katharina Ledebur (11781928)

Effect of noradrenaline (NA) alone (A) and NA with α1A- (B), α1B- (C), α1D- (D) and α1A,B,D (E)–adrenoreceptors (ARs) antagonists (a dose of 10⁻⁴ M) on the tension of co... by Barbara Jana (9110179)

Effect of noradrenaline (NA) alone (A) and NA with α1A- (B), α1B- (C), α1D- (D) and α1A,B,D (E)–adrenoreceptors (ARs) antagonists (a dose of 10⁻⁴ M) on the tension of co... by Barbara Jana (9110179)

Effect of noradrenaline (NA) alone (A) and NA with α1A- (B), α1B- (C), α1D- (D) and α1A,B,D (E)–adrenoreceptors (ARs) antagonists (a dose of 10⁻⁴ M) on the amplitude of... by Barbara Jana (9110179)

Effect of noradrenaline (NA) alone (A) and NA with α1A- (B), α1B- (C), α1D- (D) and α1A,B,D (E)–adrenoreceptors (ARs) antagonists (a dose of 10⁻⁴ M) on the frequency of... by Barbara Jana (9110179)

Effect of noradrenaline (NA) alone (A) and NA with α1A- (B), α1B- (C), α1D- (D) and α1A,B,D (E)–adrenoreceptors (ARs) antagonists (a dose of 10⁻⁴ M) on the amplitude of... by Barbara Jana (9110179)

Estimated marginal means and confidence intervals for probability of snail consumption at trial time points (12 to 72 hrs at 12 hr intervals), superimposed on the lineartime trend... by Sara M. Faiad (16979350)

S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis by Xiaolin Liu (403100)

“…We find that gene expression of s100a9 was higher in NAFL group compared with control, and was increased in NASH groups and decreased in NAFL + T2DM group compared with NAFL. …”

The importance of entry criteria from the point of view of the SD method ‐ combinations D1 –D10. by Roman Vavrek (13200141)

The importance of entry criteria from the point of view of the SD method ‐ combinations C1 –C10. by Roman Vavrek (13200141)

Mean (± standard error) of deermouse visits to the foraging stations and mean (± standard error) number of intra- and interspecific interactions of deermice (DM) among treatments (... by André V. Rubio (4594702)

Microarray analysis of genes modulated by siRNA treatments. by Giorgia Urbinati (554921)

Cardamonin induced apoptosis and decreased the MMP of ovarian cancer cells. by Peiguang Niu (17044532)

miR-146b-5p expression is decreased in monocytes of obese subjects and is regulated by globular adiponectin. by Maarten Hulsmans (181118)